Table 2. Induction of CYR61 mRNA upon oncolytic virus (OV) infection in several human glioma-derived cells and in cell lines, in vitro.
| Glioma cells | Uninfected CYR61/GAPDH |
Infected CYR61/GAPDH |
Fold induced infected/uninfected |
P value |
|---|---|---|---|---|
| Primary human glioma-derived cells | ||||
| OG02 | 45.7 | 218.8 | 4.8 | 0.00650 |
| 9.0 | 8.5 | 30.2 | 3.5 | 0.00700 |
| OGO6 | 12.1 | 34.7 | 2.9 | 0.00180 |
| 8.0 | 12.8 | 19.9 | 1.6 | 0.00310 |
| OG09 | 4.7 | 12.5 | 2.7 | 0.00030 |
| Human glioma cell lines | ||||
| LN229 | 3.3 | 30.7 | 9.3 | 0.0005 |
| U87 | 1.1 | 3.8 | 3.6 | <0.0001 |
| U343 | 4.0 | 10.0 | 2.5 | 0.0090 |
| U87ΔEGFR | 1.3 | 2.8 | 2.2 | 0.0150 |
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mRNA, messenger RNA.
The listed human glioma cell lines and patient-derived tumor cells were each treated with phosphate-buffered saline or rQNestin 34.5 for 24 hours (multiplicity of infection = 1). The cells were then harvested and analyzed by quantitative realtime PCR. The samples were analyzed for the relative amount of CYR61 in each sample. The results were normalized to the levels in a normal brain. Note the induction of CYR61 mRNA expression upon OV infection in each tumor cell line.